SCHEMBL3571897

SCHEMBL3571897

CC(C)(C)OC(=O)NCCCC(=O)N1CCc2c([nH]c3ccc(Cl)cc23)C1c1cccc(O)c1

nearest known ligand 0.69

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 19/20 0.69
KDM4E B2RXH2 1/20 0.56
MAPT P10636 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3574282 0.95 KIF11 (0.73) KIF11KDM4EMAPT
SCHEMBL3567963 0.88 KIF11 (0.77) KIF11KDM4EMAPT
SCHEMBL3580894 0.87 KIF11 (0.72) KIF11
SCHEMBL3581712 0.87 KIF11 (0.71) KIF11KDM4EMAPT
SCHEMBL3571634 0.86 KIF11 (0.74) KIF11KDM4EMAPT
SCHEMBL3571869 0.85 KDM4E (0.61) KIF11KDM4EMAPT
SCHEMBL3581984 0.85 KIF11 (0.73) KIF11KDM4EMAPT
SCHEMBL12993660 0.84 KIF11 (0.67) KIF11
SCHEMBL3578167 0.84 KIF11 (0.79) KIF11KDM4EMAPT
SCHEMBL3574847 0.84 KIF11 (0.86) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855295-B2 Tetrahydrocarboline compounds as anticancer agents NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-12-21 US disclosed
US-7855295-B2 Tetrahydrocarboline compounds as anticancer agents NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-12-21 US disclosed
US-7855295-B2 Tetrahydrocarboline compounds as anticancer agents NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-12-21 US disclosed
US-20050215580-A1 Tetrahydrocarboline compounds as anticancer agents NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215580-A1 Tetrahydrocarboline compounds as anticancer agents MTHFD1, BAD, DHFR KIF11 2735/4885KDM4E 2446/4885MAPT 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.